Spots Global Cancer Trial Database for adt
Every month we try and update this database with for adt cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Healthy Bones Study | NCT01973673 | Locally Advance... | Bone health edu... | 18 Years - | University Health Network, Toronto | |
| Collection and Measurement of Biomarkers in Prostate Cancer Radiotherapy Patients | NCT02997709 | Prostate Cancer | 30 Years - | University of Miami | ||
| Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM) | NCT02057939 | Prostate Cancer | enzalutamide Androgen Depriv... Radiation Thera... | 18 Years - | Duke University | |
| A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases | NCT04523207 | Prostatic Neopl... | Apalutamide ADT Relugolix | 18 Years - | Janssen Research & Development, LLC | |
| Trimodality Approach of Low Dose iOnizing Radiation With or Without Neoadjuvant Pembrolizumab and Prostatectomy for Men With Intermediate/High Risk Prostate Cancer (TALON) | NCT04569461 | Prostate Cancer | pembrolizumab Stereotactic bo... Short-term andr... Radical Prostat... | 18 Years - | Duke University | |
| Cardiac MRI in Measuring the Impact of Anti-androgen Treatment on Cardiac Function in Patients With Prostate Cancer | NCT02722525 | Cardiovascular ... Prostate Carcin... | Magnetic Resona... Exercise Interv... Perfusion Magne... Exercise Interv... Spectroscopy Laboratory Biom... | - | Ohio State University Comprehensive Cancer Center | |
| ARON-3 Study: International Multicentric Retrospective Study to Collect Global Experiences in the Treatment of Patients With Metastatic PCa | NCT06200558 | Prostate Cancer | 18 Years - | Hospital of Macerata | ||
| Ipilimumab + Androgen Depravation Therapy in Prostate Cancer | NCT01377389 | Prostate Cancer | Ipilimumab Leuprolide Goserelin Degarelix | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC | NCT05849298 | Prostatic Neopl... | AAA617 AAA517 Piflufolastat F... ARPI ADT Best supportive... | 18 Years - | Novartis | |
| A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC | NCT05849298 | Prostatic Neopl... | AAA617 AAA517 Piflufolastat F... ARPI ADT Best supportive... | 18 Years - | Novartis | |
| Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels | NCT02867020 | Prostate Cancer | Apalutamide Abiraterone ADT Prednisone | 18 Years - | Latin American Cooperative Oncology Group | |
| A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies | NCT05794906 | Biochemically R... | Darolutamide (B... Placebo matchin... ADT | 18 Years - | Bayer | |
| Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Prostate Cancer | NCT04599686 | Treatment | ADT SBRT | 18 Years - 99 Years | Changhai Hospital | |
| Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study | NCT06430411 | Prostate Cancer... Prostate Cancer... Prostate Cancer Prostate Neopla... Oligometastatic... Oligometastasis | Radical prostat... Prostate irradi... Surgical metast... Irradiation of ... Abiraterone ace... Enzalutamide Darolutamide Apalutamide Docetaxel Lutetium-PSMA Androgen depriv... | 18 Years - 80 Years | Medical University of Vienna | |
| ARON-3 Study: International Multicentric Retrospective Study to Collect Global Experiences in the Treatment of Patients With Metastatic PCa | NCT06200558 | Prostate Cancer | 18 Years - | Hospital of Macerata | ||
| Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy | NCT03388619 | Cancer Of Prost... Prostate Neopla... Prostate Cancer Neoplasms of Pr... Prostatic Cance... | Prostate bed wi... Prostate bed ir... Whole Body Bone... 18F-NaF PET Ima... CT mpMRI ADT | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer. | NCT06274047 | Androgen Axis S... Prostatectomy Prostate Cancer | Apalutamide Androgen Depriv... | 18 Years - | M.D. Anderson Cancer Center | |
| Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer | NCT05873192 | Prostate Cancer | ADT Enzalutamide Talazoparib Degarelix Luprolide | 18 Years - | M.D. Anderson Cancer Center | |
| Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy | NCT00776594 | Prostate Cancer | Androgen Depriv... bicalutamide bevacizumab | 18 Years - | Dana-Farber Cancer Institute | |
| Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study | NCT06430411 | Prostate Cancer... Prostate Cancer... Prostate Cancer Prostate Neopla... Oligometastatic... Oligometastasis | Radical prostat... Prostate irradi... Surgical metast... Irradiation of ... Abiraterone ace... Enzalutamide Darolutamide Apalutamide Docetaxel Lutetium-PSMA Androgen depriv... | 18 Years - 80 Years | Medical University of Vienna | |
| Tracer-Guided Surgery for Recurrent Prostate Cancer | NCT05555017 | Prostate Cancer | PSMA-radioguide... ADT | 18 Years - | The Netherlands Cancer Institute | |
| Staying Strong and Healthy During Androgen Deprivation Therapy (ADT) for Men | NCT02969577 | Prostate Cancer | Exercise Progra... Diet and Nutrit... Usual Care with... | 21 Years - | University of Kansas Medical Center | |
| Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer | NCT00658697 | Prostate Cancer | Docetaxel Bevacizumab ADT Bicalutamide | 18 Years - | Dana-Farber Cancer Institute | |
| National Danish Protocol. Surgery+ SBRT for M1 Prostate Cancer Patients | NCT04086290 | Prostate Cancer... | RARP SBRT ADT | 18 Years - | Herlev Hospital | |
| Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy | NCT00268476 | Prostate Cancer | Celecoxib Docetaxel Prednisolone ADT Zoledronic Acid Abiraterone Radiotherapy to... Enzalutamide Metformin Transdermal Oes... | - 120 Years | Medical Research Council | |
| National Danish Protocol. Surgery+ SBRT for M1 Prostate Cancer Patients | NCT04086290 | Prostate Cancer... | RARP SBRT ADT | 18 Years - | Herlev Hospital | |
| A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies | NCT05794906 | Biochemically R... | Darolutamide (B... Placebo matchin... ADT | 18 Years - | Bayer | |
| Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy | NCT03496805 | Recurrent Prost... | MGE Placebo ADT | 18 Years - | Wake Forest University Health Sciences | |
| Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer | NCT05406999 | Neoadjuvant The... High Risk Prost... Locally Advance... Intense Endocri... | ADT Abiraterone Ace... Prednisolone ta... Enzalutamide Apalutamide Darotamide Rezvilutamide PARP inhibitor Robot-assisted ... | 18 Years - 80 Years | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer | NCT04465500 | Prostate Cancer Prostate Adenoc... | External Beam R... HDR Brachythera... Androgen Depriv... | 18 Years - | University of Virginia | |
| Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy | NCT03496805 | Recurrent Prost... | MGE Placebo ADT | 18 Years - | Wake Forest University Health Sciences | |
| Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM) | NCT02057939 | Prostate Cancer | enzalutamide Androgen Depriv... Radiation Thera... | 18 Years - | Duke University | |
| The Effect of Endurance Training on Body Composition and Insulin Sensitivity in Prostate Cancer Patients Receiving Androgen Deprivation Therapy | NCT01676480 | Prostate Cancer | Endurance train... | 18 Years - | Rigshospitalet, Denmark | |
| Cardiac MRI in Measuring the Impact of Anti-androgen Treatment on Cardiac Function in Patients With Prostate Cancer | NCT02722525 | Cardiovascular ... Prostate Carcin... | Magnetic Resona... Exercise Interv... Perfusion Magne... Exercise Interv... Spectroscopy Laboratory Biom... | - | Ohio State University Comprehensive Cancer Center | |
| An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC | NCT04720157 | Prostatic Neopl... | 177Lu-PSMA-617 68Ga-PSMA-11 ARDT ADT | 18 Years - | Novartis | |
| Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer | NCT02494713 | Prostate Cancer | Degarelix Doxorubicin Ketoconazole Docetaxel Estramustine | 18 Years - | The University of Texas Health Science Center, Houston | |
| A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study. | NCT05059236 | Metastatic Horm... | Darolutamide (B... ADT | 18 Years - | Bayer | |
| Cryotherapy With or Without Short-term Adjuvant Androgen-Deprivation Therapy in Prostate Cancer | NCT01398657 | Prostate Cancer | Adjuvant Androg... | 20 Years - | National Taiwan University Hospital | |
| ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer | NCT02972060 | Prostate Cancer | ODM-201 ADT | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer | NCT04633252 | Cancer Of Prost... Prostate Neopla... | ADT Prednisone M7824 Docetaxel M9241 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| The Effect of Endurance Training on Body Composition and Insulin Sensitivity in Prostate Cancer Patients Receiving Androgen Deprivation Therapy | NCT01676480 | Prostate Cancer | Endurance train... | 18 Years - | Rigshospitalet, Denmark | |
| Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON) | NCT04748042 | Prostate Cancer Castrate Sensit... Oligometastatic... | Abiraterone Prednisone External Beam R... Androgen Depriv... Olaparib | 18 Years - | University of Michigan Rogel Cancer Center | |
| Tracer-Guided Surgery for Recurrent Prostate Cancer | NCT05555017 | Prostate Cancer | PSMA-radioguide... ADT | 18 Years - | The Netherlands Cancer Institute | |
| Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Prostate Cancer | NCT04599686 | Treatment | ADT SBRT | 18 Years - 99 Years | Changhai Hospital | |
| PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer. | NCT06274047 | Androgen Axis S... Prostatectomy Prostate Cancer | Apalutamide Androgen Depriv... | 18 Years - | M.D. Anderson Cancer Center | |
| Ipilimumab + Androgen Depravation Therapy in Prostate Cancer | NCT01377389 | Prostate Cancer | Ipilimumab Leuprolide Goserelin Degarelix | 18 Years - | M.D. Anderson Cancer Center | |
| The Role of Androgen Deprivation Treatment (ADT) in Docetaxe-Prednisolone Chemotherapy for Castrate-Resistant Prostatic Cancer | NCT01487902 | Castration-resi... | ADT No ADT | 18 Years - | Asan Medical Center | |
| A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study. | NCT05059236 | Metastatic Horm... | Darolutamide (B... ADT | 18 Years - | Bayer | |
| Cryotherapy With or Without Short-term Adjuvant Androgen-Deprivation Therapy in Prostate Cancer | NCT01398657 | Prostate Cancer | Adjuvant Androg... | 20 Years - | National Taiwan University Hospital | |
| Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer | NCT00286091 | Hormone Refract... | Denosumab Placebo | 18 Years - | Amgen | |
| Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer | NCT05873192 | Prostate Cancer | ADT Enzalutamide Talazoparib Degarelix Luprolide | 18 Years - | M.D. Anderson Cancer Center | |
| Efficacy and Safety of Apantamide Combined With Docetaxel and ADT vs. Apantamide Combined With ADT in Patients With High Tumor Burden mHSPC: a Multicenter and Prospective Cohort Study | NCT05713578 | Cohort Studies | apantamide+doce... apantamide+ADT ... | 18 Years - 90 Years | Qilu Hospital of Shandong University | |
| An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC | NCT04720157 | Prostatic Neopl... | 177Lu-PSMA-617 68Ga-PSMA-11 ARDT ADT | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
